|
Breckenridge Pharmaceutical Inc, the US subsidiary of Towa International that markets, distributes, and sells generic medicines in the US, has announced a new partnership with Maiva Pharma Pvt. Ltd. (Maiva) focused on sterile injectable products to be supplied primarily to hospitals and clinics.
The collaboration strengthens Breckenridge's position as a reliable supplier to the US hospital market, with Maiva serving as a key manufacturing partner for several injectable products.
Brian Guy, president and chief commercial officer of Breckenridge, said: "Ensuring consistent access to critical care injectables is key for our mission and for the needs of the US hospital community. This collaboration strengthens our growing presence in the hospital channel and reinforces our commitment to expanding patient access to high-quality, affordable medicines. It also represents a significant milestone in Breckenridge's evolution into three clearly defined patient-focused business lines, specialty, hospital, and retail, allowing us to better serve patients while providing healthcare providers with reliable and cost-effective treatment options."
This partnership reflects Breckenridge's ongoing investment in the dynamic hospital pharmaceutical supply chain. By partnering with Maiva Pharma, an organization with expertise in sterile injectable manufacturing, Breckenridge is expanding its capacity to support hospitals nationwide and strengthen the availability of critical medications.
Breckenridge Pharmaceutical partners with manufacturers nationwide and around the world to bring quality, cost-effective generic pharmaceuticals to US patients. With our dedication to customer service, on-time delivery, reliable supply and quality manufacturing, we strive to improve the health of the patients we and our customers serve.
In first week of March 2026, Breckenridge Pharmaceutical introduced Pomalidomide capsules, a generic version of Pomalyst by Celgene (now Bristol Myers Squibb), within the oncology therapeutic category, to strengthening its oncology portfolio. The product was developed in collaboration with Natco Pharma Limited of India.
With this launch, Breckenridge strengthens its commitment to supporting patients with complex medical conditions by delivering high-quality, affordable treatment options to those who need them most. Breckenridge's introduction of Pomalidomide capsules also further expands the company's specialty oncology generics portfolio.
Pomalidomide capsules, a thalidomide analogue, is indicated for the treatment of adult patients with?multiple myeloma?who have received at least two prior therapies including lenalidomide and a proteasome inhibitor and have demonstrated disease progression on or within 60 days of completion of the last therapy. It is also approved for?AIDS-related Kaposi sarcoma?after failure of highly active antiretroviral therapy, as well as for HIV-negative adult patients with Kaposi sarcoma. The product is available in?1 mg, 2 mg, 3 mg, and 4 mg strengths and is distributed primarily through specialty pharmacies and clinics.
Maiva Pharma is a leading sterile injectable manufacturer supplying more than 45 products to the US market. Backed by over three decades of sterile manufacturing expertise, Maiva has built a strong reputation for delivering high-quality, reliable injectable solutions to global pharmaceutical partners. The company operates two state-of-the-art manufacturing facilities on the outskirts of Bengaluru, India, and employs approximately 1,200 highly skilled professionals. Maiva's comprehensive sterile capabilities include liquid, lyophilized, and suspension injectables in vials, as well as IV bags, with ongoing expansion into prefilled syringes and cartridge systems. With a commitment to quality, compliance, and operational excellence, Maiva Pharma continues to strengthen its position as a trusted partner to the global healthcare industry.
|